All In Biotech

NDA 215870 · Exela Pharma

Fentanyl Citrate

Fentanyl Citrate · Intravenous

Discontinued

Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Feb 8, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,750

243 Phase 3, 113 recruiting

FAERS reports

17,840

15,772 serious, 6,175 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 8, 2023 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
2 products under this application
  • FENTANYL CITRATE · FENTANYL CITRATE EQ 2.5MG BASE/50ML (EQ 0.05MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION, INTRAVENOUS · Discontinued
  • FENTANYL CITRATE · FENTANYL CITRATE EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION, INTRAVENOUS · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Fentanyl" as an intervention, any sponsor and status, largest first.

All 1,750 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dependence3,935
  • overdose2,456
  • death2,065
  • drug abuse1,737
  • toxicity to various agents1,385
  • ill-defined disorder1,288
  • cardiac arrest918
  • respiratory arrest737
  • drug ineffective715
  • drug hypersensitivity628
  • nausea607
  • pain574

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200472
2005115
2006235
2007154
2008261
2009272
20101,148
2011563
2012696
2013404
2014429
2015510
2016595
20171,230
20181,319
20191,207
20201,031
2021760
2022834
20234,700
2024599
2025432
2026272

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Fentanyl Citrate (Fentanyl Citrate)

2024 spending

$886K

Beneficiaries

59

510 claims

Per beneficiary

$15,016

$13.76 per unit

View as table
YearSpending
2020$1,457,692
2021$1,366,922
2022$1,233,015
2023$1,389,859
2024$885,973

Part D: Fentanyl Citrate* (Fentanyl Citrate/PF)

2024 spending

$53K

Beneficiaries

13,577

15,510 claims

Per beneficiary

$4

$1.61 per unit

View as table
YearSpending
2020$17,226
2021$38,448
2022$65,012
2023$72,933
2024$53,186

Part B: Fentanyl Citrate (Fentanyl Citrate/PF) · HCPCS J3010

2024 spending

$181K

Beneficiaries

37,082

50,336 claims

Per beneficiary

$5

2024 ASP limit $0.93 per unit

View as table
YearSpending
2020$400,962
2021$290,935
2022$274,248
2023$261,592
2024$180,781

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 7,032 on PubMed

Sponsor: Exela Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.